Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Stomach Neoplasms 32Carcinoma, Hepatocellular 22Carcinoma, Non-Small-Cell Lung 16Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Colorectal Neoplasms 11Sarcoma 9Lung Neoplasms 9Nasopharyngeal Carcinoma 7Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Head and Neck Neoplasms 5Glioma 5Esophageal Neoplasms 5Cholangiocarcinoma 5Recurrence 4Pancreatic Neoplasms 4Osteosarcoma 4Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Advanced Gastric Cancer 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Neoplasm Metastasis 3NSCLC 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

apatinib 2nimotuzumab 1fluorapacin 1Standard of Care 1Neoadjuvant Therapy 1Decision Support Techniques 1Control Groups 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Advanced Cancer × apatinib × Clear all
NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second Hospital

Phase 1 Unknown
60 enrolled

Advanced Cancer

NCT03243643 2017-09-08

HS:Hansoh;

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
80 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡